Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation

ObjectivesOur objective was to examine gender differences in clinical presentation, management and prognosis of atrial fibrillation (AF) in a contemporary cohort.MethodsIn 6412 patients, 39.7% women, of the PREvention oF thromboembolic events – European Registry in Atrial Fibrillation, we examined g...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Heart (British Cardiac Society) Ročník 103; číslo 13; s. 1024 - 1030
Hlavní autori: Schnabel, Renate B, Pecen, Ladislav, Ojeda, Francisco M, Lucerna, Markus, Rzayeva, Nargiz, Blankenberg, Stefan, Darius, Harald, Kotecha, Dipak, Caterina, Raffaele De, Kirchhof, Paulus
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England BMJ Publishing Group LTD 01.07.2017
BMJ Publishing Group
Edícia:Original research article
Predmet:
Age Factors
Aged
Anticoagulants - therapeutic use
Atrial Fibrillation - complications
Atrial Fibrillation - drug therapy
Atrial Fibrillation - epidemiology
Cardiac arrhythmia
Cardiac Risk Factors and Prevention
Catheters
Europe - epidemiology
Female
Follow-Up Studies
Gender differences
Humans
Incidence
Male
Prognosis
Registries
Retrospective Studies
Risk Factors
Sex Distribution
Sex Factors
Stroke
Survival Rate - trends
Thromboembolism - epidemiology
Thromboembolism - etiology
Thromboembolism - prevention & control
Time Factors
Womens health
European registry
Atrial fibrillation
gender differences
ISSN:1355-6037, 1468-201X, 1468-201X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:ObjectivesOur objective was to examine gender differences in clinical presentation, management and prognosis of atrial fibrillation (AF) in a contemporary cohort.MethodsIn 6412 patients, 39.7% women, of the PREvention oF thromboembolic events – European Registry in Atrial Fibrillation, we examined gender differences in symptoms, risk factors, therapies and 1-year incidence of adverse outcomes.ResultsMen with AF were on average younger than women (mean±SD: 70.1±10.7 vs 74.1±9.7 years, p<0.0001). Women more frequently had at least one AF-related symptom at least occasionally compared with men (95.4% in women, 89.8% in men, p<0.0001). Prescription of oral anticoagulation was similar, with an increase of non-vitamin K antagonist oral anticoagulants from 5.9% to 12.6% in women and from 6.2% to 12.6% in men, p<0.0001 for both.Men were more frequently treated with electrical cardioversion and ablation (20.6% and 6.3%, respectively) than women (14.9% and 3.3%, respectively), p<0.0001. Women had 65% (OR: 0.35; 95% CI (0.22 to 0.56)) lower age-adjusted and country-adjusted odds of coronary revascularisation, 40% (OR: 0.60; (0.38 to 0.93)) lower odds of acute coronary syndrome and 20% (OR: 0.80; (0.68 to 0.96)) lower odds of heart failure at 1 year. There were no statistically significant gender differences in 1-year stroke/transient ischaemic attack/arterial thromboembolism and major bleeding events.ConclusionIn a ‘real-world’ European AF registry, women were more symptomatic but less likely to receive invasive rhythm control therapy such as electrical cardioversion or ablation. Further study is needed to confirm that these differences do not disadvantage women with AF.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1355-6037
1468-201X
1468-201X
DOI:10.1136/heartjnl-2016-310406